id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2136-0007,FDA,FDA-2022-E-2136,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:03:57Z,,0,0,09000064868c5103
FDA-2022-E-2136-0006,FDA,FDA-2022-E-2136,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T13:00:39Z,,0,0,09000064863a94be
FDA-2022-E-2136-0005,FDA,FDA-2022-E-2136,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-11T05:00:00Z,2024,1,2024-01-11T05:00:00Z,,2024-01-11T21:26:10Z,,0,0,090000648638f1ef
FDA-2022-E-2136-0004,FDA,FDA-2022-E-2136,Determination of Regulatory Review Period for Purposes of Patent Extension; Truseltiq,Notice,Determinations,2023-12-07T05:00:00Z,2023,12,2023-12-07T05:00:00Z,2024-02-06T04:59:59Z,2023-12-07T15:08:31Z,2023-26885,0,0,090000648630ab6a
FDA-2022-E-2136-0003,FDA,FDA-2022-E-2136,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-01-18T05:00:00Z,2023,1,2023-01-18T05:00:00Z,,2023-01-18T20:54:16Z,,0,0,09000064855f6c3d
FDA-2022-E-2136-0001,FDA,FDA-2022-E-2136,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-09-06T04:00:00Z,2022,9,2022-09-06T04:00:00Z,,2022-09-06T14:51:55Z,,0,0,09000064852b50d9
FDA-2022-E-2136-0002,FDA,FDA-2022-E-2136,Patent Extension Application from Novartis AG,Other,Application,2022-09-06T04:00:00Z,2022,9,2022-09-06T04:00:00Z,,2022-09-06T14:52:02Z,,0,0,09000064852b50db